NICE fast-tracks epilepsy recommendation

Doctors are now able to prescribe Epidyolex with clobazam – a seizure-preventing cannabis-based treatment – to eligible people, including children, with the severe epilepsy types Lennox Gastaut syndrome and Dravet syndrome.

Following an agreement between NHS England agreement and GW Pharma, the National Institute for Health and Care Excellence (NICE) has been able to recommend the treatment, with access fast tracked and available from January 6.

Clinical trials have shown the treatment could reduce the number of seizures by up to 40 per cent in some children when used in combination with clobazam. 

“Living with or caring for someone with severe epilepsy is exceptionally challenging, especially as there are so few treatments available for the rare forms of the condition,” said Simon Stevens, NHS chief executive. “Thousands of people, including children, will now have access to this treatment, which has the potential to make a real difference.”

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Training Matters's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.